JOINN Laboratories board changes, lease renewals, and R&D agreements approved

JOINN Laboratories (China) Co., Ltd. held its Second Extraordinary General Meeting of 2025, approving resolutions including amendments to its articles of association, dissolution of the supervisory committee, and the election of an employee director, Ms. Li Ye. Shareholders also approved various proposed amendments to corporate governance policies.

Concurrently, the company renewed its Biorichland Lease for its California facilities, extending the term until December 31, 2028. The annual rent for the leased premises is $730,992.00 in 2026, $752,921.76 in 2027, and $775,509.41 in 2028, with an additional $2,226.33 per month for leased equipment. This is classified as a connected transaction.

Furthermore, JOINN Laboratories entered into two 2026 continuing connected transactions: the Staidson Research and Development Service Framework Agreement with an annual cap of RMB47 million for 2026, and the BioAI Service Framework Agreement with an annual cap of RMB16.5 million for 2026. These transactions cover pharmaceutical R&D services and software development, respectively, with Ms. Feng and Mr. Gao abstaining from voting due to conflicts of interest.